Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Operating Expenses (2022 - 2024)

Amylyx Pharmaceuticals has reported Other Operating Expenses over the past 3 years, most recently at $37.0 million for Q3 2024.

  • Quarterly results put Other Operating Expenses at $37.0 million for Q3 2024, up 609.31% from a year ago — trailing twelve months through Jun 2025 was $37.0 million (down 73.26% YoY), and the annual figure for FY2024 was $160.8 million, up 532.19%.
  • Other Operating Expenses for Q3 2024 was $37.0 million at Amylyx Pharmaceuticals, up from $7.4 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for AMLX hit a ceiling of $116.4 million in Q1 2024 and a floor of $172000.0 in Q3 2022.
  • Median Other Operating Expenses over the past 3 years was $5.6 million (2023), compared with a mean of $21.0 million.
  • Biggest five-year swings in Other Operating Expenses: surged 2933.72% in 2023 and later skyrocketed 32.94% in 2024.
  • Amylyx Pharmaceuticals' Other Operating Expenses stood at $2.8 million in 2022, then skyrocketed by 231.8% to $9.4 million in 2023, then skyrocketed by 295.43% to $37.0 million in 2024.
  • The last three reported values for Other Operating Expenses were $37.0 million (Q3 2024), $7.4 million (Q2 2024), and $116.4 million (Q1 2024) per Business Quant data.